))
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leading Out in Innovation of Hypertension Treatment
Manage episode 395931776 series 3529176
Content provided by podcast@investorbrandnetwork.com. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by podcast@investorbrandnetwork.com or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Hypertension, or high blood pressure, is rampant in America. An estimated 45% of adults in the United States, or 108 million people, have hypertension, yet only about one out of every four have their condition under control. That’s a big problem considering hypertension increases risks for heart disease and stroke, which are, respectively, the no. 1 and no. 5 leading causes of death in the nation each year. To that point, the CDC names hypertension as a primary or contributing cause in nearly half a million deaths annually in the U.S. Hypertension treatment options vary tremendously from meditation to conventional drugs, with what looks to be a promising new innovation on the horizon from Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). Lexaria is proving that its proprietary DehydraTECH(TM) technology repeatedly delivers strong therapeutic responses, without the side effects of today’s drugs. Lexaria is looking to throw its hat into the ring with majors in the market today that are making billions of dollars by treating high blood pressure and other leading causes of death, including Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Moderna Inc. (NASDAQ: MRNA).
56 episodes
Share
